Biosimilars Market Access in Psoriatic Arthritis
Biosimilars Market Access in Psoriatic Arthritis
$2,995.00
Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriatic arthritis market. These market leaders, however, face patent expirations and consequent biosimilar launches.
Publisher: Datamonitor Healthcare
- Description
- Contents
- Samples
Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriatic arthritis market. These market leaders, however, face patent expirations and consequent biosimilar launches. Payers are eager to leverage these changes in the competitive landscape and enact pro-biosimilar access measures, resulting in downward pricing pressures and/or continuing market erosion for first-generation TNF-alpha inhibitors. The rate of this erosion is likely to be gradual initially, as both physicians and payers are not likely to advocate patient switching.
CONTENTS
4 EXECUTIVE SUMMARY
5 US
5 Inflectra carries biosimilar labeling designation, but is not interchangeable
5 Physicians hesitant to use biosimilars, but understand that payers may hold sway
8 Bibliography
9 FIVE MAJOR EU MARKETS
9 Insights and strategic recommendations
9 Uptake of biosimilar TNF-alpha inhibitors varies across EU markets as the EMA does not determine interchangeability
9 Most physicians and payers consider biosimilars to be interchangeable, and an opportunity to reduce costs, but worries around indication extrapolation remain
11 Payers use biosimilars to pressure originators on pricing
12 Hospitals continue to procure both biosimilars and originators; dynamic pricing environment observed
15 Biosimilars will be used as price benchmarks for pipeline agents
16 Payers are unlikely to implement strong incentives to drive uptake of biosimilar infliximab due to limited use of the drug
21 Bibliography
23 METHODOLOGY
23 Primary research
LIST OF TABLES
20 Table 1: Market access tools used to promote biosimilar uptake in the five major EU markets, by country
Table 1: Market access tools used to promote biosimilar uptake in the five major EU markets, by country
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Big Pharma Licensing Trends, 2012–16 
Sign up to the